Labelling of cytotoxic medicines
The correct labels and product information to use on cytotoxic medicine and waste products.
Employers must take precautions to keep safe those employees who administer cytotoxic medicines to patients. After administration, patients mainly eliminate cytotoxic medicines in their urine or bile. But all bodily substances can be contaminated with either the:
How long bodily substances are contaminated with cytotoxic medicines will differ for individual drugs and patients. Cancer Institute NSW (eviQ) recommends following cytotoxic precautions for a standard period of seven days from administration, although care should be taken to identify drugs with extended excretion.
Exposure to cytotoxic medicines can occur through:
To ensure that cytotoxic medicines are provided safely, employers should consider:
Workplace procedures should be available for all areas where:
When designing and setting up an area to administer cytotoxic medicine and care for patients in a healthcare setting, employers should consider the following controls:

The correct labels and product information to use on cytotoxic medicine and waste products.
For patients who need cytotoxic precautions at home, these controls should be in place where reasonably practicable. Patients should be given information on what controls they could consider and how to follow them at home. This may depend on the individual circumstances. Also see the following sections:
All employees involved with administering cytotoxic medicines must be given the information, instruction, training or supervision they need to work safely.
Employer duties to ensure that employees are properly trained to handle cytotoxic medicines.
Equipment that helps to administer cytotoxic medicines can greatly reduce the risk of exposure. This equipment can include:
Risk control measures to safely deal with spills of cytotoxic medicine and related waste.
Using PPE to help control the risks of handling cytotoxic medicines.
As an employer, you should ensure that standard work procedures for administering cytotoxic medicines clearly detail how to:
The intravesical route is used to treat bladder cancer. The chemotherapy drugs are administered via a urinary catheter, which is inserted into the bladder via the urethra. There are specific risk control measures to consider when this treatment is offered. These include:
Topical cytotoxic agents may be in the form of ointments, lotions or eyedrops. Control measures when administering topical agents include:
Oral cytotoxic medicines are generally given as tablets and capsules. Control measures when administering oral medicines include:
Oral dose forms should only be manipulated if a pharmacist recommends it. This includes tablets and capsules. Manipulation may be needed when a patient is:
Crushing or breaking should only happen:
Pharmacy can advise on other forms or dosing strategies (including dissolution). This will help to minimise chances of exposure and environmental contamination.
For more information, see:
Risk control measures to safely store, prepare and transport cytotoxic medicines.
Employees may sometimes administer cytotoxic medicines in a patient's home. To minimise the risk of clinical employees and others being exposed to cytotoxic medicines and waste, consider:
Patients treated at home or in a community care setting should be given the means to help them safely deal with a cytotoxic spill for up to seven days after treatment, unless the administered drug has extended expiry. This should include:
Spill containment instructions for the home setting may be as follows:
Exposure to cytotoxic waste can occur through:
Handling any bodily fluid from a patient treated with cytotoxic medicines. For example:
This includes handling any vessel used to receive bodily fluids, such as:
Whenever cytotoxic medicine is administered, employees should note:
This formal process will help employees to work out if any body fluids from the patient may be contaminated, requiring cytotoxic-specific precautions.
When patients leave a treatment facility, they often still need cytotoxic-specific precautions. This includes for their body fluids. Treating facilities should explain to patients and their carers:
It is important that the treating facility:
If a patient is being transferred to another ward or facility after receiving cytotoxic medicines, the treating facility should ensure:
The treating facility should develop procedures for:
When moving a patient to another area within a hospital or treating centre, employers need to ensure the following control measures are in place:
Employers must give employees the information, instruction, training or supervision they need to work safely. For example, employees at the patient's new destination should be:
The same requirements apply to transport by ambulance if required.
This information is from WorkSafe's Handling cytotoxic medicines in the workplace guidance. The complete guide is available in two formats.